Hepatitis B and C Therapeutics Market Surges to US$17.02 Billion in 2024 as Innovation, National Screening Policies, and Next-Gen Antivirals Transform Global Care | According to DataM Intelligence

Buy This Report with Year-End Offer (Buy 1 report: Get 30% OFF | Buy 2 reports: Get 50% OFF each! Limited time offer): https://www.datamintelligence.com/buy-now-page?report=hepatitis-b-and-c-therapeutics-market  Buy This Report with Year-End Offer  ( Buy 1 report: Get 30% OFF | Buy 2 reports: Get 50% OFF each! Limited time offer):https://www.datamintelligence.com/buy-now-page?report=hepatitis-b-and-c-therapeutics-market   Market Dynamics: Strong Push from Antiviral Innovation, Screening...

AUSTIN, Texas, 19/11/2025 (informazione.news - comunicati stampa - salute e benessere)

Buy This Report with Year-End Offer (Buy 1 report: Get 30% OFF | Buy 2 reports: Get 50% OFF each! Limited time offer): https://www.datamintelligence.com/buy-now-page?report=hepatitis-b-and-c-therapeutics-market 

Market Dynamics: Strong Push from Antiviral Innovation, Screening Mandates, and Real-World Evidence Programs

The market's expansion is driven by a combination of regulatory reforms, new product approvals, and the shift toward simplified, pan-genotypic therapies. The adoption of tenofovir and entecavir for HBV continues to remain robust, while the transition to direct-acting antivirals (DAAs) has transformed HCV care, reducing treatment durations from 24–48 weeks to as low as 8–12 weeks.

LSI keywords integrated: HBV therapeutics, HCV antivirals, chronic viral hepatitis drugs, DAA market, nucleotide analogues, liver disease burden, screening expansion, immunomodulators.

Key growth factors influencing the 2024–2033 outlook include:

Detailed Market Segmentation with 2024 Market Size and Shares

By Indication: Hepatitis B (HBV) vs. Hepatitis C (HCV)

In 2024, the market remained dominated by Hepatitis C therapeutics, supported by the strong commercial performance of direct-acting antivirals. Of the total US$17.02 billion market, HCV therapeutics accounted for approximately US$10.9 billion, representing 64% of global revenues. This dominance is driven by high cure rates, short treatment durations, and aggressive payer funding to eradicate the disease burden.

Meanwhile, Hepatitis B therapeutics generated nearly US$6.12 billion, accounting for 36% of the market in 2024. Despite lower growth relative to HCV, HBV therapeutics benefit from lifelong treatment regimens, rising vaccination uptake, and increasing research activity in functional cure mechanisms such as siRNA-based therapies, capsid assembly modulators, and T-cell immune enhancers.

By Route of Administration: Oral vs. Injectable Therapies

Oral formulations accounted for the largest share of the market in 2024, with revenues reaching US$13.21 billion, equivalent to 77.6% of global market value. The predominance of oral antivirals is linked to their effectiveness, patient convenience, and widespread availability across both retail and hospital channels.
Injectable therapeutics-including interferon-based therapy and novel immune-targeted biologics-represented US$3.81 billion, or 22.4%. Although historically declining, the segment has seen renewed interest in 2024 due to the development of long-acting immunotherapies for HBV functional cure programs.

By Distribution Channel: Hospital vs. Retail Pharmacies

Hospital pharmacies maintained a significant share of the market in 2024, contributing US$ 9.18 billion (54%) of total revenues as complex HCV regimens and high-risk HBV cases necessitated specialist intervention. Retail pharmacies accounted for US$ 7.84 billion (46%), supported by increased availability of DAAs through prescription-based community channels, especially in the U.S., Germany, and Japan.

Download PDF Brochure: https://www.datamintelligence.com/download-sample/hepatitis-b-and-c-therapeutics-market 

Browse in-depth TOC on "Hepatitis B & C Therapeutics Market" 

72 – Tables
67 – Figures
210 – Pages

Regional Analysis: Strong Momentum in the USA and Japan

United States Market Overview

The U.S. accounted for approximately 41% of the global hepatitis B and C therapeutics market in 2024, representing a market size of US$ 7.0 billion.

Key 2024–2025 quantitative drivers:

Latest News:

Japan Market Overview

Japan represented approximately 12% of the global market, translating to a market size of US$2.04 billion in 2024. The country maintains one of the strongest national commitments to hepatitis elimination globally, reinforced by extensive universal screening and subsidized antiviral access.

Recent quantitative developments:

Latest News:

Competitive Landscape: Top Companies Strengthening Their Portfolio

The competitive landscape remains dominated by global pharmaceutical leaders with extensive antiviral portfolios. Companies are investing aggressively in immune-targeting candidates, real-world evidence programs, and pan-genotypic innovation.

Top 5 Companies by 2024 Revenue (Global Revenues Across All Products)

Within the hepatitis therapeutics category, Gilead, AbbVie, Merck, and Bristol-Myers Squibb remain highly dominant due to their strong patent portfolios, high cure rates, and extensive distribution networks.

Request for Customized Sample Report as per Your Business Requirement: https://www.datamintelligence.com/customize/hepatitis-b-and-c-therapeutics-market 

Future Outlook: Market Transition Toward Functional Cure and Long-Acting Therapies

The next decade will see a clear pivot toward functional cure strategies for HBV, an area where ongoing clinical trials involving siRNA therapies, core protein assembly modulators, and T-cell–directed immunotherapies show promising potential. The success of these new mechanisms could materially reshape the market landscape by reducing the burden of lifelong therapy, increasing compliance, and expanding the addressable patient population.

For HCV, the market will continue to mature with high cure rates, but opportunities remain in improving access across lower-income regions, integrating digital adherence systems, and expanding pan-genotypic RWE datasets.

As the global market approaches US$ 20.83 billion by 2033, companies with strong R&D investment, cost-optimized supply chains, and government-backed procurement agreements will maintain the strongest growth positions.

About DataM Intelligence

DataM Intelligence is a renowned provider of market research, delivering deep insights through pricing analysis, market share breakdowns, and competitive intelligence. The company specializes in strategic reports that guide businesses in high-growth sectors such as nutraceuticals and AI-driven health innovations.

To find out more, visit https://www.datamintelligence.com/ or follow us on Twitter, LinkedIn, and Facebook.

Contact:
Sai Kiran
DataM Intelligence 4market Research LLP
Ground floor, DSL Abacus IT Park, Industrial Development Area
Uppal, Hyderabad, Telangana 500039
USA: +1 877-441-4866
Email: Sai.k@datamintelligence.com 

Logo: https://mma.prnewswire.com/media/1858619/3573087/DataM_Intelligence_Logo.jpg

 

 

View original content:https://www.prnewswire.co.uk/news-releases/hepatitis-b-and-c-therapeutics-market-surges-to-us17-02-billion-in-2024-as-innovation-national-screening-policies-and-next-gen-antivirals-transform-global-care--according-to-datam-intelligence-302620140.html